Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
about
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironmentDiagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.Measure for measure: minimal residual disease in CLL.Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsPharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Recent advances in therapy of chronic lymphocytic leukaemia.Clinical Trials in the Genomic Era.Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.Single cell analysis of normal and leukemic hematopoiesis.A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.Recent therapeutic advances in chronic lymphocytic leukemia.Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.Chronic lymphocytic leukaemia
P2860
Q37097867-CA509A81-581C-4041-ACF8-9E71865E938DQ37429218-040010C0-83C5-4B15-80E1-DA056B521D21Q37508066-78B1CB99-E311-4DE1-9940-3C0C4966016FQ37528067-6CE062D9-B4DC-4E66-97D2-F7EF6ECF7C34Q38672646-32BB4D86-4E85-4FC6-AB64-1A12A2AF07E0Q38719429-617D8233-045C-4490-9B2A-DDA582B571C2Q38789282-156B007F-C7FA-4D78-8E52-BB661A808F5FQ38818283-14AB0680-6BD7-4C84-9346-C84910EEED8CQ38862525-B72590A0-0FF2-4216-8633-70D507F70164Q38905607-0C4D4DD7-A9FF-4546-8A84-630BF82E35D3Q39420524-A8287FDE-D6B9-4170-84C7-E45D2CE49129Q40126133-5D354960-94F9-4D4F-A8FC-C2EE8A2904DDQ42777547-D6D4396F-24C4-4D08-B9B5-080C21169116Q45051052-1D84117A-8440-4984-ADE5-CECFA2A19814Q46318389-4C9D48A5-2DD3-4F0E-AF2E-B105CC8E1623Q47873950-7173858B-41FB-493E-82E1-778A00F9D023Q48152651-C4CEB36C-B8F4-43FA-8109-ED94213E0571Q48762439-95049021-B30E-499D-92D4-139047CE4391Q50121608-C0941FEC-F939-4D71-A1EC-D933A8B210E5Q52690102-7A8C3D3C-C264-4DE0-AB84-56D1BE0D55B0Q52770382-0DA463F9-AF93-4A6D-8787-1747D28357EAQ52812536-D333FFEC-1512-4D86-9DF9-115E1302CC17Q53963822-FD356CF9-A5BA-413E-BE43-FF169A1A9066Q55644886-781E100D-7A8A-406A-9DEF-6F219AA162C2Q56270980-F36EEED0-20CA-4487-A59F-A47C2A8DBB3E
P2860
Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Eliminating minimal residual d ...... rd cure for patients with CLL.
@en
type
label
Eliminating minimal residual d ...... rd cure for patients with CLL.
@en
prefLabel
Eliminating minimal residual d ...... rd cure for patients with CLL.
@en
P2860
P1433
P1476
Eliminating minimal residual d ...... rd cure for patients with CLL.
@en
P2093
Philip A Thompson
P2860
P304
P356
10.1182/BLOOD-2015-08-634816
P407
P577
2015-11-17T00:00:00Z